Abstract:Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are important components of the highly active antiretroviral therapy (HAART) used to treat human immunodeficiency type 1 virus (HIV-1). However, because of the emergence of drug resistance and the adverse effects of current anti-HIV drugs, it is essential to develop novel NNRTIs with an excellent safety profile, improved activity against NNRTI-resistant viruses, and enhanced activity against clinical isolates of different subtypes. Here, we have identified 1-[(benzyloxy)methyl] -6-(3,5-dimethylbenzyl)-5-iodopyrimidine-2,4(1H,3H)-dione (WPR-6), a novel NNRTI with a 50% effective concentration (EC50) of 2 to 4 nM against laboratory-adapted HIV-1 strain SF33 and an EC50 of 7 to 14 nM against nucleoside reverse transcriptase inhibitor-resistant HIV-1 strain 7391 with a therapeutic index of >1 x 10(4). A panel of five representative clinical virus isolates of different subtypes circulating predominantly in China was highly sensitive to WPR-6, with EC(50)s ranging from 1 to 6 nM. In addition, WPR-6 showed excellent antiviral potency against the most prevalent NNRTI-resistant viruses containing the K103N and Y181C mutations. To determine whether WPR-6 selects for novel resistant mutants, in vitro resistance selection was conducted with laboratory-adapted HIV-1 strain SF33 on MT-4 cells. The results demonstrated that V1061 and Y188L were the two dominant NNRTI-associated resistance mutations detected in the breakthrough viruses. Taken together, these in vitro data indicate that WPR-6 has greater efficacy than the reference HEPT analogue TNK651 and the marketed drug nevirapine against HIV-1. However, to develop it as a new NNRTI, further improvement of its pharmacological properties is warranted.

The HEPT analogue, 1-((benzyloxy) methyl)-6-(3, 5-dimethylbenzyl)-5- iodopyrimidine-2, 4(1H, 3H)-dione (WPR-6), is active against a broad spectrum of HIV-1 strains of different subtypes with drug-resistance

Development of Novel HEPT Analogs Featuring Significantly Improved Anti-Resistance Potency Against HIV-1 Through Chemical Space Exploration of the Tolerant Region I.

Design, Synthesis, and Biological Evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils As Potent Hiv-1 Non-Nucleoside Reverse Transcriptase Inhibitors with an Improved Drug Resistance Profile

Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.

Discovery of Novel Dihydrothiopyrano[4,3- d ]pyrimidine Derivatives as Potent HIV-1 NNRTIs with Significantly Reduced hERG Inhibitory Activity and Improved Resistance Profiles

Discovery of novel diarypyrimidine derivatives bearing six-membered non-aromatic heterocycles as potent HIV-1 NNRTIs with improved anti-resistance and drug-like profiles

Identification of novel diarylpyrimidine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against wild-type and K103N mutant viruses

2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies

Development of Novel Dihydrofuro[3,4- d ]pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C

Inhibitory activity of 9-phenylcyclohepta[ d ]pyrimidinedione derivatives against different strains of HIV-1 as non-nucleoside reverse transcriptase inhibitors

Structure-based design of diarylpyrimidines and triarylpyrimidines as potent HIV-1 NNRTIs with improved metabolic stability and drug resistance profiles

Design and synthesis of Fsp3‐enriched spirocyclic‐substituted diarylpyrimidine derivatives as novel HIV‐1 NNRTIs

Structure-guided Design of Novel Biphenyl-Quinazoline Derivatives As Potent Non-Nucleoside Reverse Transcriptase Inhibitors Featuring Improved Anti-Resistance, Selectivity, and Solubility

Structure-based Design of Novel Heterocycle-Substituted ATDP Analogs As Non-Nucleoside Reverse Transcriptase Inhibitors with Improved Selectivity and Solubility

Design, synthesis, and biological evaluation of benzo[4,5]thieno[2,3- d ]pyrimidine derivatives as novel HIV-1 NNRTIs

Structure-directed expansion of biphenyl-pyridone derivatives as potent non-nucleoside reverse transcriptase inhibitors with significantly improved potency and safety

Discovery of Novel Amino Acids (Analogues)-Substituted Thiophene[3,2- d]pyrimidine Derivatives as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Design, Synthesis, and Biological Evaluation

Structure-based design and optimization lead to the identification of novel dihydrothiopyrano[3,2- d]pyrimidine derivatives as potent HIV-1 inhibitors against drug-resistant variants

Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors

Structure-Based Discovery of Novel NH2-Biphenyl-Diarylpyrimidines As Potent Non-Nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Safety: from NH2-Naphthyl-Diarylpyrimidine to NH2-Biphenyl-Diarylpyrimidine.

Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy.